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Abstract. Ovarian cancer is the most lethal gynecological 
cancer among women worldwide. Adverse side effects and 
acquired resistance to conventional platinum based chemo-
therapy are major impediments in ovarian cancer treatment, 
and drive the development of more selective anticancer drugs 
that target cancer-specific defects. In this study, theaflavin-3, 
3'-digallate (TF3), the major theaflavin monomer in black tea, 
exhibited a potent growth inhibitory effect on the cisplatin-
resistant ovarian cancer A2780/CP70 cells (IC50, 23.81 µM), 
and was less cytotoxic to a normal ovarian IOSE-364 cells 
(IC50, 59.58 µM) than to the cancer cells. Flow cytometry 
analysis indicated that TF3 induced preferential apoptosis 
and G2 cell cycle arrest in A2780/CP70 cells with respect 
to IOSE-364 cells. TF3 induced apoptosis through both the 
intrinsic and extrinsic apoptotic pathways, and caused G2 
cell cycle arrest via cyclin B1 in A2780/CP70 cells. The p53 
protein played an important role in TF3-induced apoptosis and 
G2 cell cycle arrest. TF3 might upregulate the p53 expression 
via the Akt/MDM2 pathway. Our findings help elucidate the 
mechanisms by which TF3 may contribute to the prevention 
and treatment of platinum-resistant ovarian cancer.
Introduction
Ovarian cancer is the second most common and the most lethal 
of malignancies arising in the female reproductive system (1). 
Response rates to first-line platinum-based therapy are >80%, 
but the overall 5-year survival rate for patients with advanced 
ovarian cancer is only ~20% because of acquired drug 
resistance and adverse side effects. Therefore, overcoming 
drug resistance is the key to successful treatment of ovarian 
cancer, and the development of novel therapeutic approaches 
is urgently needed (2).
Apoptosis is an active death process genetically encoded 
that can be triggered by a wide variety of extra- and intra-
cellular stimuli. Recent evidence suggests that the failure 
of drug-induced apoptosis may be an underlying cause of 
drug resistance. Molecular mechanisms of failed apoptosis 
in chemoresistant ovarian cancer cells include p53 muta-
tions, abnormal expression of the Bcl-2 family proteins and 
P-glycoproteins, and upregulation of other inhibitors of 
apoptosis that block caspases and stabilize the mitochondrial 
permeability pore. Triggering apoptosis is one of the potential 
strategies to overcome chemoresistance (3,4). The cell cycle is 
a series of events that take place in a cell leading to its division 
and duplication that produces two daughter cells. This process 
involves four sequential phases that go from quiescence 
(G0 phase) to proliferation (G1, S, G2, and M phases) and back 
to quiescence. A disregulation of the cell cycle components 
may lead to tumor formation. A number of potential molecular 
targets for novel anticancer drug discovery have been identi-
fied in cell cycle control mechanisms (5,6).
It is a common belief that compounds from fruits, 
vegetables and other foods will help reduce the risk of various 
chronic diseases including cancer, and have less side effects 
(7). Black tea is the most widely consumed beverage world-
wide, and accounted for ~80% of the dried tea manufactured 
annually (8). It was reported that black tea extract possess 
potently antiproliferative property against a variety of cancer 
cells in vitro and in vivo (9,10). In particular, the previous 
prospective cohort study showed that black tea was a main 
dietary source of flavonols for US women, and its intake was 
associated with lower risk of ovarian cancer (11).
Theaflavins are major bioactive components in black tea, 
and contribute importantly to properties of black tea including 
its color, ‘mouth feel’ and extent of tea cream formation. 
They possess a benzotropolone skeleton that is formed from 
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co-oxidation of appropriate pairs of catechins during the 
production of black tea (12). The major theaflavins in black tea 
are theaflavin (TF1), theaflavin-3-gallate (TF2A), theaflavin-
3'-gallate (TF2B) and theaflavin-3, 3'-digallate (TF3), and TF3 
(Fig. 1) is usually most abundant among them (13). Theaflavins 
have been demonstrated to inhibit proliferation and induce 
apoptosis in a variety of cancer cells including human breast 
cancer MCF-7 cells, malignant melanoma A375 cells and oral 
squamous carcinoma hSC-2 cells. In addition, theaflavins are 
responsible for the inhibition of ROS-potentiated Ah109A 
adhesion and invasion to the cultured rat mesothelial cell 
monolayer (14-17).
Although theaflavins have received considerable attention 
for their anticancer activity, their effect on the ovarian cancer 
is still not clear. Therefore, the aim of this study was to inves-
tigate the apoptotic and cell cycle arrest effects of TF3 in the 
platinum-resistant ovarian cancer cell line A2780/CP70 and 
a normal ovarian surface epithelial cell line IOSE-364. The 
possible mechanisms underlying these modulations of TF3 on 
the ovarian cancer cells were also examined.
Materials and methods
Cell culture and reagents. The platinum-resistant human 
ovarian cancer cell line A2780/CP70 (p53 wild-type) was a 
generous gift from Dr Β. Jiang at West Virginia University. 
IOSE-364, a normal ovarian surface epithelial cell line, 
was presented by Dr Ν. Auersperg at University of British 
Columbia, Canada. The cells were cultured in RPMI-1640 
medium (Sigma) supplemented with 10% fetal bovine 
serum (FBS) (Invitrogen) at 37˚C in a humidified incubator 
with 5% CO2. Theaflavin-3, 3'-digallate (TF3, >90.0%) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
primary antibodies against Bcl-xL, Bad, p21, p53, MDM2 
and GAPDh were obtained from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA). The primary antibodies against 
caspase-8 and -9, Puma, Bax, cyclin B1, phospho-cdc2 (Tyr15), 
cdc2, DR5, FADD, phospho-Akt (Thr180/Tyr182) and total-
Akt were purchased from Cell Signaling Technology, Inc. 
(Danvers, MA, USA).
Cell viability assay. The cell viability was assessed a using 
3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay. Briefly, the cells (1x104 cells per well) 
were seeded in 96-well plate and incubated overnight. Then 
various concentrations of TF3 (0-50 µM) were added, and an 
equal amount of DMSO was used as control. After treatment 
for 24 h, 20 µl of MTT (5 mg/ml) was added to each well 
and incubated for an additional 4 h at 37˚C in the dark. The 
medium was discarded, and the formazan crystals formed in 
the cells were dissolved in 200 µl DMSO. The optical density 
was measured at 570 nm using a Synergy™ hT Multi-Mode 
Microplate Reader (BioTek).
Flow cytometric analysis of apoptotic cells. The apoptotic cell 
death was determined using an Alexa Fluor® 488 Annexin V/
Dead Cell Apoptosis kit (Invitrogen). After exposure to TF3 
(0-20 µM) for 24 h, cells were harvested, centrifuged for 
10 min at 1500 rpm and then washed twice with PBS. Cells 
were suspended in binding buffer with Alexa Fluor 488 
Annexin V and propidium iodide (PI) for 15 min. The stained 
cells were analyzed by flow cytometry (FACSCalibur system, 
BD Biosciences), measuring the fluorescence emission at 530 
and 575 nm using 488 nm excitation.
Flow cytometry analysis of the cell cycle. Cells treated with 
TF3 (0-20 µM) for 24 h were digested with trypsin and 
harvested by 1500 rpm centrifugation for 10 min. The cell 
pellet was suspended with 70% ethanol at -20˚C overnight, 
washed with PBS, then incubated with 180 µg/ml Rnase A at 
37˚C for 15 min. After 15 min staining with 50 µg/ml PI in the 
dark at 37˚C, the samples were analyzed by flow cytometry 
(FACSCalibur system, BD Biosciences). Data were plotted 
and analyzed by using FCS Software (De novo Software, Los 
Angeles, CA, USA).
Caspase-3/7 assay. The caspase-3/7 activities in A2780/CP70 
and IOSE-364 cells were detected using a Caspase-Glo 3/7 
Assay kit (Promega). Cells were seeded in 96-well plates at 
1x104 cells/well, incubated overnight, and treated with TF3 
(0-20 µM) for 24 h. After treatment, 100 ml of caspase-3/7 
reagent were added to each well, mixed and incubated for 
1 h at room temperature. Luminescence was measured using 
a Synergy™ hT Multi-Mode Microplate Reader (BioTek). 
Caspase-3/7 activities were normalized by total protein levels, 
and were expressed as percentage of the untreated control. 
The total protein levels were measured with a BCA assay kit 
(Pierce).
Western blotting. A2780/CP70 ovarian cancer cells were 
seeded in 60-mm dishes at 1x106 cells/dish, incubated over-
night, and treated with 0-20 µM TF3 for 24 h. Then cells were 
harvested with M-PER Mammalian Protein Extraction Reagent 
(Pierce) supplemented with halt Protease and Phosphatase 
Inhibitor (Pierce), and total protein levels were assayed with 
BCA Protein assay kit (Pierce). Cell lysates were separated by 
SDS-PAGE and blotted onto nitrocellulose membrane with a 
Mini-Protean 3 System (Bio-Rad). The membrane was blocked 
with 5% skim milk, and then incubated with specific primary 
antibodies and appropriate secondary antibodies conjugated 
with horseradish peroxidase. The antigen-antibody complex 
was visualized with the ECL kit (Pierce). Protein bands were 
quantitated with nIh Image J software and normalized by 
GAPDh bands for analysis.
Transfection with small interfering RNA (siRNA). A2780/
CP70 ovarian cancer cells were seeded in 60-mm dishes at 
5x105 cells/dish, incubated overnight, and then transfected 
with p53 siRnA (Santa Cruz) using Lipofectamine 2000 trans-
fection reagent (Invitrogen) according to the manufacturer's 
protocol. Cells transfected with control siRnA (Santa Cruz) 
were used as controls. After a 24-h transfection period, cells 
were treated with TF3 (0-20 µM) for 24 h. Cell lysates were 
collected for western blot analysis.
Statistical analysis. In this study, all samples were prepared 
and analyzed in triplicate. The data are presented as means 
± standard deviations (SD). Multiple comparisons were 
performed by one-way analysis of variance (AnOVA) 
followed with Student-newman-Keuls (SnK) test. Statistical 
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differences between two groups were evaluated using the 
Student's t-test. All statistical analyses of data were performed 
using Statistical Analysis System (SAS) for windows V8. A 
p<0.05 was considered statistically significant, and p<0.01 
was considered statistically highly significant.
Results
Effect of TF3 on A2780/CP70 and IOSE-364 cell viability. 
The cytotoxicity of TF3 on A2780/CP70 and IOSE-364 cells 
was analyzed using the MTT assay. As shown in Fig. 2, TF3 
inhibited the growth of both the cell types in a dose-dependent 
manner. The cell viability with TF3 treatment (0-50 µM) for 
24 h ranged from 100 to 11.38% for A2780/CP70 cells, and 
from 100 to 58.14% for IOSE-364 cells. The IC50 values of 
TF3 for A2780/CP70 and IOSE-364 cells were estimated to 
be 23.81 and 59.58 µM, respectively. These results indicated 
that TF3 had lower cytotoxic effect against normal ovarian 
IOSE-364 cells than ovarian cancer A2780/CP70 cells.
TF3 induces apoptosis in A2780/CP70 cells. To investigate 
whether TF3 inhibited cell viability by inducing apoptosis in 
A2780/CP70 and IOSE-364 cells, the cells were treated with 
TF3 (0-20 µM) for 24 h and subsequently subjected to double 
staining with Annexin V FITC and propidium iodide (PI) 
followed by flow cytometry analysis. As shown in Fig. 3A, 
the treatment of TF3 increased the total percent of apoptotic 
cells (upper right quadrant + low right quadrant) from 3.28 
to 22.47% in A2780/CP70 cells, but could hardly induce 
apoptosis of IOSE-364 cells in the test range of 0-20 µM. 
To confirm that TF3 induced apoptosis, caspase-3/7 enzy-
matic activities were evaluated in both cell lines. As shown 
in Fig. 3B, treatment with TF3 maximally increased the 
caspase-3/7 enzymatic activity to 2.19- and 1.20-fold of that 
in controls for A2780/CP70 and IOSE-364 cells, respectively 
(p<0.05), indicating that TF3 had more potential to induce 
apoptosis in the ovarian cancer cells than the normal ovarian 
cells in this study.
TF3 induces G2 cell cycle arrest in A2780/CP70 cells. To 
determine whether the growth inhibitory effect of TF3 is 
caused by specific perturbation of cell cycle-related events, cell 
cycle phase distribution of cells treated with TF3 (0-20 µM) 
for 24 h was analyzed by flow cytometry after propidium 
iodide staining. As shown in Fig. 4 and Table I, treatment 
Figure 1. Chemical structure of TF3 used in this study.
Figure 2. Effect of TF3 on cell growth in human ovarian cancer cells A2780/
CP70 and normal ovarian cells IOSE-364. Cells (1x104/well) were seeded in 
96-well plates, incubated overnight, and then treated with TF3 for 24 h. Cell 
viability was determined by MTT assay. Data represent means ± SD from 
three independent experiments. Significant differences among the treatments 
are indicated by different letters (p<0.05).
Table I. Cell cycle phase distribution of A2780/CP70 and 
IOSE-364 cells with TF3 treatment.
 Cell cycle phase distribution
 ---------------------------------------------------------------------------------------
Cell lines TF3 % G1 % G2 % S
 (µM)
A2780/CP70   0 42.47±1.33a 18.00±1.22d 39.53±2.65a,b
   5 39.32±2.71a 25.04±0.79c 35.64±1.87b
 10 26.57±1.26b 29.08±0.86b 44.35±3.37a
 20 21.81±1.94c 39.78±1.73a 38.41±2.83a,b
IOSE-364   0 32.93±0.85a 32.91±1.47b 34.16±1.93a
   5 31.52±2.23a 35.35±2.39b 33.14±2.61a
 10 29.55±2.71a 39.08±1.24a 31.37±1.06a
 20 30.32±1.64a 39.59±1.67a 30.08±2.27a
Data represent means ± SD from three independent experiments. 
Values in a column followed by different letters are significantly 
different (p<0.05).
TU et al:  APOPTOSIS AnD G2 ARREST By ThEAFLAVIn-3, 3'-DIGALLATE2660
Figure 3. TF3 induces apoptosis in A2780/CP70 and IOSE-364 cells. (A) Flow cytometry of TF3 treated A2780/CP70 and IOSE-364 cells using a double-
staining method with FITC-conjugated Annexin V and PI. The upper left and low left quadrant indicate the percentage of dead and live cells, respectively, and 
the upper right and low right quadrants indicate the percentage of late and early apoptotic cells, respectively. (B) Caspase-3/7 activity levels with TF3-treatment 
for 24 h. The caspase-3/7 activity of the control cells after treatment was arbitrarily expressed as 100%. Data represent means ± SD of three independent 
experiments. Significant differences among the treatments are indicated by different letters (p<0.05).
Figure 4. TF3 induces cell cycle arrest in A2780/CP70 and IOSE-364 cells. Cells were treated with various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h, 
fixed in 70% ethanol, and stained with propidium iodide. DnA contents were determined by flow cytometry.
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of A2780/CP70 and IOSE-364 cells with TF3 resulted in a 
significant increase in the proportion of cells at the G2 phase 
in a concentration-dependent manner (p<0.05). The G2 phase 
percentage of the A2780/CP70 cells increased by 21.78%, 
while that of IOSE-364 cells increased by 6.68% after 20 µM 
TF3 treatment for 24 h. These results suggested that TF3 
had more potent capability to induce G2 cell cycle arrest for 
ovarian cancer cells than the ovarian normal cells.
Effect of TF3 on the intrinsic apoptotic pathway in A2780/
CP70 cells. Apoptosis can be initiated via two canonical path-
ways: the intrinsic or mitochondrial pathway, and the extrinsic 
or receptor-mediated pathway. To clarify whether the intrinsic 
pathway is involved in TF3-induced apoptosis of A2780/CP70 
cells, we examined the protein expression of pro-apoptotic 
Bcl-2 family proteins (Puma, Bax and Bad), anti-apoptotic 
Bcl-2 family protein Bcl-xL, and caspase-9 by western blot-
ting. Fig. 5 shows TF3 significantly increased the protein levels 
of Bax, Bad and cleaved caspase-9, reduced protein expres-
sions of Bcl-xL and procaspase-9 (p<0.05), and had no effect 
on Puma protein expression (p>0.05). These results suggested 
that TF3 induced apoptosis in A2780/CP70 cells through the 
intrinsic apoptotic pathway.
Effect of TF3 on the extrinsic apoptotic pathway in A2780/
CP70 cells. next, we investigated whether TF3 could activate 
the extrinsic apoptotic pathway in A2780/CP70 cells. As 
shown in Fig. 6, TF3 significantly increased protein expres-
sion of DR5, FADD and cleaved caspase-8, and decreased the 
protein level of procaspase-8 (p<0.05). These results indicated 
Figure 5. Effect of TF3 on the intrinsic apoptotic pathway in A2780/CP70 
cells. Protein lysates were prepared from A2780/CP70 cells after treatment 
with various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. Puma, Bax, 
Bad, Bcl-xL and caspase-9 protein levels were analyzed by western blotting. 
The quantification histograms are shown with error bars. Data represent 
means ± SD from three independent experiments. Significant differences 
among the treatments are indicated by different letters (p<0.05).
Figure 6. Effect of TF3 on the extrinsic apoptotic pathway in A2780/CP70 
cells. Protein lysates were prepared from A2780/CP70 cells after treatment 
with various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. DR5, 
FADD, procaspase-8 and cleaved caspase-8 protein levels were analyzed by 
western blotting. The quantification histograms are shown with error bars. 
Data represent means ± SD from three independent experiments. Significant 
differences among different treatments are indicated by different letters 
(p<0.05).
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that the extrinsic pathway was involved in TF3-induced apop-
tosis of A2780/CP70 cells.
Effect of TF3 on cell cycle G2-related proteins. To investigate 
the underlying mechanism of the G2 arrest induced by TF3 in 
A2780/CP70 cells, we evaluated the effect of TF3 on cell cycle 
regulatory proteins that play important roles in G2 cell cycle 
progression by western blot analysis. As shown in Fig. 7, TF3 
could effectively suppress cyclin B1 expression (p<0.05), but 
had no effect on the protein levels of p21, phospho-cdc2 (Tyr15) 
or total-cdc2 (p>0.05). These results implied that the down-
regulation of cyclin B1 protein expression may be responsible 
for the G2 growth arrest induced by TF3 in A2780/CP70 cells.
Role of p53 in TF3-induced apoptosis and cell cycle arrest. 
The p53 signaling pathway is a well-known crucial modulator 
of cell survival, apoptosis and cell cycle arrest (18). To clarify 
the role of p53 in TF3-induced apoptosis and cell cycle arrest, 
p53 protein expression was determined by western blotting. 
Fig. 8A shows that TF3 upregulated the protein expression of 
p53 in A2780/CP70 cells (p<0.05). To further analyze the role 
of p53 in TF3-induced cell death, p53 was selectively knocked 
down by siRnA approach. Fig. 8B shows that p53 protein level 
was obviously inhibited after treatment with 50 nM p53 siRnA 
(p<0.01). This p53 depletion led to abrogation of TF3-induced 
decrease in cyclin B1, procaspase-8 and procaspase-9 protein 
expression (p<0.05). These results suggested that TF3 induced 
Figure 7. Effect of TF3 on cell cycle G2-related proteins in A2780/CP70 cells. 
Protein lysates were prepared from A2780/CP70 cells after treatment with 
various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. p21, cyclin B1, 
phospho-cdc2 and total-cdc2 protein expression levels were analyzed by 
western blotting. The quantification histograms are shown with error bars. 
Data represent means ± SD from three independent experiments. Significant 
differences among the treatments are indicated by different letters (p<0.05).
Figure 8. Role of p53 in TF3-induced apoptosis and G2 cell cycle arrest of 
A2780/CP70 cells. The quantification histograms are shown with error bars. 
Data represent means ± SD from three independent experiments. (A) The 
effects of TF3 on the protein expression of p53 determined by western blot-
ting. Significant differences among the treatments are indicated by different 
letters (p<0.05). (B) The effects of p53 siRnA (50 nM) on the protein expres-
sion of procaspase-8, procaspase-9 and cyclin B1 determined by western 
blotting. *p<0.05, **p<0.01, compared with respective controls.
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apoptosis and G2 cell cycle arrest at least partly through p53 
in A2780/CP70 cells.
Regulation of phospho-Akt, total-Akt and MDM2 protein 
expression by TF3. Akt is considered as a determinant of 
cisplatin resistance in ovarian cancer cells (19). Murine double 
minute 2 (MDM2) is an important negative regulator of p53 
that directly inhibits p53 transcriptional activity and enhances 
p53 degradation via the ubiquitin-proteasome pathway (20). 
Therefore, we tested the effects of TF3 on the expression of Akt 
and its downstream effector MDM2. As shown in Fig. 9, TF3 
significantly decreased the phosphorylation of Akt without 
the influence on total Akt protein expression, and reduced the 
protein level of MDM2 (p<0.05).
Discussion
Although cisplatin-centered chemotherapy is the first-line 
anticancer agent for human ovarian cancer, chemoresistance 
and adverse side effects remain major hurdles to successful 
treatment (21). natural products have recently received 
renewed focus as a rich repository for drug discovery (22). 
(-)-Epigallocatechin-3-gallate (EGCG), the most abundant 
catechin monomer in green tea, was reported to potently 
suppress ovarian cancer cell growth alone, and potentiate the 
inhibiting effect of sulforaphane on paclitaxel-resistant ovarian 
cancer cell lines (23). TF3 is the oxidation product of (-)-epicat-
echin gallate (ECG) and EGCG, and has been found to possess 
stronger antioxidant and anti-inflammation activities compared 
with EGCG (8,24). These findings stimulated our interest in 
investigating the effect of TF3 on the ovarian cancer cells.
In this study, we found that the IC50 value of TF3 for 
A2780/CP70 was 23.81 µM, which was around half of the IC50 
(59.58 µM) for TF3 in the IOSE-364 cells (Fig. 2), and that 
(47.9 µM) for cisplatin in the A2780/CP70 cells as reported 
in our previous study (25). Flow cytometry analysis and 
caspase-3/7 activity assay suggested that TF3 had more poten-
tial to induce apoptosis and G2 cell cycle arrest of A2780/CP70 
cells with respect to IOSE-364 cells (Figs. 3 and 4), which 
provided a possible explanation for the preferential cell growth 
inhibitory effect by TF3.
A decreased susceptibility of ovarian cancer to apoptosis 
was strongly associated with drug resistance (26). Agents that 
target the apoptotic pathway have been shown to sensitize 
tumor cells to chemotherapy and radiotherapy (27). Apoptosis 
can be initiated via the intrinsic and extrinsic pathways, which 
both ultimately activate the same effector caspases (3, 6 and 7) 
and apoptosis effector molecules. The intrinsic apoptosis 
pathway is triggered by intracellular signals such as cellular 
and DnA damage. Key events are the depolarization of the 
mitochondrial membrane potential and the release of mito-
chondrial factors such as cytochrome c into the cytosol, which 
results in activation of initiator caspase-9. Mitochondrial acti-
vation is critically controlled by the family of Bcl-2 proteins, 
which consists of pro- and anti-apoptotic members (28). The 
extrinsic pathway implicates the activation of death receptors 
at the plasma membrane level. Tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) interacts with the death 
domain-containing receptors DR4/DR5 or Fas, resulting 
in the recruitment of Fas-associated death domain (FADD), 
procaspase-8, and procaspase-10 to form the death-inducing 
signaling complex (DISC) (29). It was reported that the 
differential induction of apoptosis in cancer versus normal 
cells involves direct targeting of mitochondria associated 
with alterations in the balance of Bcl-2 proteins (30). Another 
explanation is that normal cells are resistant to the tumor 
necrosis factor related apoptosis-inducing ligand (TRAIL) 
due to the high TRID levels, whereas tumor lines carrying 
TRAIL-receptors in most cases can not be protected (31). 
Theaflavins have been reported to target the Fas/caspase-8 
pathway to induce apoptosis in human breast cancer cells, and 
influence Bcl-2 protein expression in an experimental lung 
cancer mouse model (32,33). In this study, treatment with TF3 
significantly regulated the protein expression of Bcl-2 family 
proteins (Bax, Bad and Bcl-xL), DR5, FADD, caspase-8 and 
-9 (Figs. 5 and 6), indicating that TF3 induced apoptosis 
through both intrinsic and extrinsic pathways in A2780/CP70 
cells. Induction of apoptosis might account for the preferential 
inhibitory effect of TF3 on ovarian cancer A2780/CP70 cells 
vs. normal ovarian IOSE-364 cells.
Figure 9. Effect of TF3 on Akt/MDM2 pathway in A2780/CP70 cells. Protein 
lysates were prepared from A2780/CP70 cells after treatment with various 
concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. phospho-Akt, total-Akt 
and MDM2 protein expression levels were analyzed by western blotting. The 
quantification histograms are shown with error bars. Data represent means 
± SD from three independent experiments. Significant differences among the 
treatments are indicated by different letters (p<0.05).
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Cancer is a disease of inappropriate cell proliferation. It 
was revealed that many cancer cells have defective G1 check-
point mechanisms, and depend on G2 checkpoint during cell 
replication far more than normal cells. These insights have 
given birth to the idea of cell cycle G2 checkpoint abrogation 
as a cancer cell specific therapy (34). Our cell cycle analysis 
showed that TF3 induced more prominent G2 arrest in A2780/
CP70 cells than in IOSE-364 cells (Fig. 4 and Table I), 
suggesting that in addition to apoptosis, G2 cell cycle arrest 
was another factor that contributed to the preferential cell 
growth inhibition. Transition through G1 to S phase is regu-
lated by the cyclin A-Cdk2 and cyclin E-Cdk2 complexes. 
Inactivation of cyclin B-Cdc2 leads to the G2/M arrest (35). 
The p21 protein is a potent cyclin-dependent kinase inhibitor, 
and functions as a regulator of cell cycle progression at G1 
and G2 phase (36). A previous study showed that theaflavins 
induced G2/M arrest by modulating expression of p21, cdc25C 
and cyclin B in human prostate carcinoma PC-3 cell (37). 
however, our data showed that TF3 could not influence the 
p21, phospho-cdc2 (Tyr15) and total-cdc2 protein levels, but 
significantly decreased cyclin B1 expression (Fig. 7), indi-
cating cyclin B1 played an important role in the TF3-induced 
G2 arrest of A2780/CP70 cells.
The tumor suppressor protein, p53, transcriptionally 
activates genes that control cell cycle arrest, apoptosis, and 
other cellular processes that help to prevent tumor develop-
ment. p53 stimulates apoptosis by a wide network of signals 
including the extrinsic pathway such as Killer/DR5 and 
Fas/APO-1, and intrinsic pathway including proteins Bax, 
Puma and noxa (38). In addition, p53 contributes to cell 
cycle arrest, blocking the cell at the G1, S or G2/M phase 
by inducing expression of p21 and the consequent inhibition 
of cyclin D/Cdks, decreasing cyclin B1 transcription and 
synthesis, or inactivates Cdc2 through Cdc25C (39). It is of 
particular interest in ovarian cancer in view of the association 
of platinum sensitivity and p53 pathway alterations. however, 
wild-type p53 status is often, but not always, associated with 
cisplatin sensitivity (40).
It is known that A2780/CP70 cell line has a wild-type 
p53 gene sequence (41). In this study, we found that TF3 
significantly increased the p53 protein expression (Fig. 8A). 
Furthermore, transfection with the p53 siRnA tended to 
attenuate the reduction of procaspase-8, 9 and cyclin B1 
protein expression induced by TF3 (Fig. 8). These results 
suggested that p53 played an important role in TF3 induced 
apoptosis and G2 cell cycle arrest of A2780/CP70 cells, which 
was consistent with the previous reports that p53 promoted 
theaflavin-induced apoptosis in human breast and prostate 
cancer cells through mitochondrial death cascade (42,43), and 
prevented G2/M transition by decreasing intracellular levels of 
cyclin B1 protein in ovarian cancer Ts-SKOV3 cells (44).
Akt is a serine/threonine kinase that plays a critical role 
in the malignant transformation of human tumors and their 
subsequent growth, proliferation, and metastasis. Targeted 
inhibition of the Akt pathway is a promising strategy for cancer 
therapy and can also be useful for overcoming chemotherapy 
resistance (45). The functional link between Akt-mediated 
chemoresistance and p53 has been found. It was reported that 
Akt could induce an MDM2-dependent downregulation of 
p53, and suppression of Akt sensitized chemoresistant cells to 
cisplatin in a p53-dependent manner (46). Our data showed 
that TF3 treatment significantly decreased the phosphoryla-
tion of Akt and MDM2 protein level, indicating that TF3 
might upregulate p53 expression through inactivation of Akt 
and MDM2 in A2780/CP70 cells. Further in vivo studies in 
animal models and human patients are necessary to ascertain 
the anticancer effect of theaflavins against ovarian cancer.
In conclusion, this study demonstrated that TF3 had a 
potent and preferential cell growth inhibitory effect on the 
cisplatin-resistant ovarian cancer cell line A2780/CP70 with 
respect to normal cell line IOSE-364 via apoptosis and G2 cell 
cycle arrest. TF3 induced apoptosis through both the intrinsic 
and extrinsic pathways, and caused G2 cell cycle arrest via 
cyclin B1 in A2780/CP70 cells. These activities were at least 
partly mediated by p53 upregulation dependent of Akt and 
MDM2. Based on these results, TF3 would be a promising 
natural compound for prevention and treatment of platinum-
resistant ovarian cancer.
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